Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
REGULATORY
Xolair Faces 37.3% Price Slash, Keytruda 20.9% in April: MHLW
Japan on March 5 announced new NHI prices for listed medicines, effective April 1, revealing a 37.3% slash for Novartis Pharma’s Xolair (omalizumab) after its label expansion into pollen allergy, and a further 20.9% reduction for MSD’s fast-growing blockbuster Keytruda…
To read the full story
Related Article
- Novartis Says Only 3,000 Pollen Allergy Patients Used Xolair This Season, Less than 10% of Re-Pricing Line
May 10, 2021
- 7 Generic API Specifications Subject to New Rule to Address Unreasonable Price Rises
March 6, 2020
- 3 Drugs Earn Post-Launch “True Clinical Utility” Premium; Forxiga Price Flat, Rises for Canaglu and Praluent
March 5, 2020
- Price Maintenance Premium Granted to 335 APIs/555 Products; Novartis Top PMP Earner
March 5, 2020
- With 80%-Plus Gx Rates, Many One-Time Blockbusters Might Be In for Earlier “G1” Price Cuts
March 5, 2020
- Xolair’s Re-Pricing Decided, but Regulators and Novartis Were at Odds over Patient Projections
March 2, 2020
- Nasal Steroid Used as “Reference Drug” for Xolair in Special Re-Pricing
January 23, 2020
- Japan’s Special Re-Pricing Rules to Hit 17 Drugs in April; Potentially Big Slash for Keytruda, Lixiana
January 22, 2020
- Xolair Faces New Special Re-Pricing Rule; Keytruda, Lixiana Caught by Huge-Seller Price Slash
January 21, 2020
- Xolair’s Use Would Be Limited to 1-3% of Pollen Allergy Patients in Japan: Specialist
January 20, 2020
REGULATORY
- MHLW Drafts Guideline Update, Urges Makers to Factor Distribution Costs into WPPs
December 16, 2025
- MHLW to Add Company-Driven Route to “Specific-Use Drug” Designations
December 16, 2025
- MHLW Council Determines 3 “Drug Loss” Products as High-Need, to Seek Development
December 16, 2025
- LDP Biosimilar Group Submits Request to Finance Minister, Seeks Continued Support
December 16, 2025
- LDP’s Patch League Urges Finance Minister to Continue Coverage, Support Prices
December 16, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…